Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human intra-arterial iPS-NKT cell infusion for recurrent or advanced head and neck cancer
jRCT2033200116Phase 1Active, not recruiting
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Start
- Sep 2020
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BP1209 in head and neck squamous cell carcinoma (HNSCC), sponsored by BrightPath Biotherapeutics Co., Ltd. Primary endpoint: Incidence of dose-limiting toxicity at each dose. Started Sep 2020; status: active, not recruiting.
02
Drugs
BP1209
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2033200116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033200116.